Technical Analysis for PIRS - Pieris Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
A 17.30 0.29% 0.05
PIRS closed up 0.29 percent on Friday, November 1, 2024, on 37 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Nov 12
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
BB Squeeze Ended Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 50 DMA Bullish 0.29%
Expansion Pivot Buy Setup Bullish Swing Setup 0.29%
Bollinger Band Squeeze Range Contraction 0.29%
Gapped Up Strength 0.29%
Overbought Stochastic Strength 0.29%
Fell Below 50 DMA Bearish 2.55%
20 DMA Support Bullish 2.55%

   Recent Intraday Alerts

Alert Time
Gap Down Closed about 21 hours ago
Expansion Pivot Buy Entry about 21 hours ago
Rose Above Previous Day's High about 21 hours ago
Rose Above Upper Bollinger Band about 21 hours ago
Up 1% about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pieris Pharmaceuticals, Inc. Description

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Anticalin proteins are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on development of two drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases. It is also developing PRS-110, a monovalent antagonist that is used for the treatment of various types of cancers, including renal, gastric, and lung carcinomas, as well as central nervous system tumors and sarcomas; and PRS-300series of Anticalin proteins in immuno-oncology. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Inflammatory Diseases Kidney Disease Dialysis Asthma Membrane Technology Sarcoma Carcinoma Hepatology Chronic Kidney Disease End Stage Renal Disease Kidney Renal Disease Blood Plasma Stage Renal Disease Central Nervous System Tumors Hepcidin Iron Deficiency

Is PIRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.2
52 Week Low 6.2
Average Volume 12,446
200-Day Moving Average 13.61
50-Day Moving Average 16.93
20-Day Moving Average 16.68
10-Day Moving Average 16.95
Average True Range 0.44
RSI (14) 60.16
ADX 7.86
+DI 24.48
-DI 20.91
Chandelier Exit (Long, 3 ATRs) 16.15
Chandelier Exit (Short, 3 ATRs) 17.35
Upper Bollinger Bands 17.44
Lower Bollinger Band 15.93
Percent B (%b) 0.91
BandWidth 9.01
MACD Line 0.17
MACD Signal Line 0.10
MACD Histogram 0.0644
Fundamentals Value
Market Cap 1.71 Billion
Num Shares 98.9 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -50.88
Price-to-Sales 0.35
Price-to-Book 0.53
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.86
Resistance 3 (R3) 17.85 17.66 17.76
Resistance 2 (R2) 17.66 17.52 17.66 17.73
Resistance 1 (R1) 17.48 17.43 17.57 17.49 17.70
Pivot Point 17.29 17.29 17.34 17.29 17.29
Support 1 (S1) 17.11 17.15 17.20 17.12 16.90
Support 2 (S2) 16.92 17.06 16.92 16.87
Support 3 (S3) 16.74 16.92 16.84
Support 4 (S4) 16.75